The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The History & Future of Anti-Citrullinated Protein Antibodies (ACPAs)

The History & Future of Anti-Citrullinated Protein Antibodies (ACPAs)

March 18, 2019 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Dr. Fox

Dr. Fox

David Fox, MD, a professor of rheumatology at the University of Michigan, Ann Arbor, says, “I think the key paper that really explained what was going on was this Journal of Clinical Investigation paper in 1998 from van Venrooij’s group.”8

You Might Also Like
  • A Close Look at Antibodies in RA
  • ACR/ARHP Annual Meeting 2012: Can Studying Anticitrullinated Protein Antibodies Put Us on Track to Stop RA?
  • PAD4 Antibodies May Help Predict Treatment Response in Rheumatoid Arthritis
Explore This Issue
March 2019
Also By This Author
  • Can Peripheral Spondyloarthritis Be Reversed?

This team from The Netherlands made a breakthrough in solving the mystery and identifying the antigenic target. They demonstrated that the amino acid citrulline was an essential part of the antigens recognized by the anti-filaggrin autoantibodies. They also figured out that there was a post-translational modification of arginine to citrulline, explaining why the autoantibodies were not picked up in non-fully differentiated filaggrin or in recombinant filaggrin.8

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Therefore, this antibody group could be more properly categorized as anti-citrullinated peptide/protein antibodies. Adds Dr. Fox, “This paper showed indeed that it was citrullination that was generating not just one autoantigen, but a group of autoantigens that these antibodies could recognize.” It was eventually found that a wide array of citrullinated proteins are recognized by these autoantibodies.

Citrullination

Citrullination refers to a post-translational modification that can be performed on a number of different proteins, including histones, vimentin, fibrinogen, filaggrin and type II collagen. The enzyme peptidyl arginine deiminase (PAD) modifies the genomic amino acid arginine to citrulline—an amino acid not specifically encoded in the genome, but which is only created as a post-translational modification.9 Citrullination is now thought to be essential for many important biological processes, including the formation and release of some types of neutrophil extracellular traps (NETs) by neutrophils. In tissue marked by inflammation, the process of citrullination is now known to be widespread.4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Holers explains that citrullination is one of the processes that appears to be fundamental to inflammation, as well as to many intracellular immune regulatory processes that continue to be identified. He also notes this process often changes the function of the citrullinated protein.

“With neutrophils, it’s believed that citrullination of histones allows chromatin to unwind to allow certain types of NETs to be formed,” he says. “In skin keratinocyte differentiation, it is thought to be necessary for filaggrin to be processed. Citrullination can also help to control gene regulation, and thus it is thought to be an epigenetic modifier of gene function.”

It is currently believed that under physiologically normal conditions, the immune system only rarely encounters citrullinated proteins, which are usually intracellular. Citrullination is a normal process in many dying cells, however. These may then release citrullinated proteins into the extracellular matrix, or they may release PAD itself, which may continue to citrullinate various extracellular proteins.7

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Citrullination itself is thought to augment inflammation, although the situation is complex and not yet well characterized. Though citrullination is found in inflamed tissue in many different inflammatory diseases, ACPAs are highly specific for rheumatoid arthritis.4

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: anti-citrullinated protein antibody (ACPA), Lost & FoundIssue: March 2019

You Might Also Like:
  • A Close Look at Antibodies in RA
  • ACR/ARHP Annual Meeting 2012: Can Studying Anticitrullinated Protein Antibodies Put Us on Track to Stop RA?
  • PAD4 Antibodies May Help Predict Treatment Response in Rheumatoid Arthritis
  • Anti-Drug Antibodies May Affect RA Treatment

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)